225 related articles for article (PubMed ID: 14585987)
1. The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents.
Hirose Y; Katayama M; Stokoe D; Haas-Kogan DA; Berger MS; Pieper RO
Mol Cell Biol; 2003 Nov; 23(22):8306-15. PubMed ID: 14585987
[TBL] [Abstract][Full Text] [Related]
2. Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence.
Hirose Y; Katayama M; Mirzoeva OK; Berger MS; Pieper RO
Cancer Res; 2005 Jun; 65(11):4861-9. PubMed ID: 15930307
[TBL] [Abstract][Full Text] [Related]
3. Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells.
Hirose Y; Berger MS; Pieper RO
Cancer Res; 2001 Aug; 61(15):5843-9. PubMed ID: 11479224
[TBL] [Abstract][Full Text] [Related]
4. Cooperative function of Chk1 and p38 pathways in activating G2 arrest following exposure to temozolomide.
Hirose Y; Katayama M; Berger MS; Pieper RO
J Neurosurg; 2004 Jun; 100(6):1060-5. PubMed ID: 15200121
[TBL] [Abstract][Full Text] [Related]
5. DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system.
Caporali S; Falcinelli S; Starace G; Russo MT; Bonmassar E; Jiricny J; D'Atri S
Mol Pharmacol; 2004 Sep; 66(3):478-91. PubMed ID: 15322239
[TBL] [Abstract][Full Text] [Related]
6. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.
Curtin NJ; Wang LZ; Yiakouvaki A; Kyle S; Arris CA; Canan-Koch S; Webber SE; Durkacz BW; Calvert HA; Hostomsky Z; Newell DR
Clin Cancer Res; 2004 Feb; 10(3):881-9. PubMed ID: 14871963
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents.
Liu L; Taverna P; Whitacre CM; Chatterjee S; Gerson SL
Clin Cancer Res; 1999 Oct; 5(10):2908-17. PubMed ID: 10537360
[TBL] [Abstract][Full Text] [Related]
8. Loss of DNA mismatch repair imparts defective cdc2 signaling and G(2) arrest responses without altering survival after ionizing radiation.
Yan T; Schupp JE; Hwang HS; Wagner MW; Berry SE; Strickfaden S; Veigl ML; Sedwick WD; Boothman DA; Kinsella TJ
Cancer Res; 2001 Nov; 61(22):8290-7. PubMed ID: 11719462
[TBL] [Abstract][Full Text] [Related]
9. The Mre11/Rad50/Nbs1 complex interacts with the mismatch repair system and contributes to temozolomide-induced G2 arrest and cytotoxicity.
Mirzoeva OK; Kawaguchi T; Pieper RO
Mol Cancer Ther; 2006 Nov; 5(11):2757-66. PubMed ID: 17121922
[TBL] [Abstract][Full Text] [Related]
10. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.
Liu L; Markowitz S; Gerson SL
Cancer Res; 1996 Dec; 56(23):5375-9. PubMed ID: 8968088
[TBL] [Abstract][Full Text] [Related]
11. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells.
Hirose Y; Berger MS; Pieper RO
Cancer Res; 2001 Mar; 61(5):1957-63. PubMed ID: 11280752
[TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.
Tentori L; Portarena I; Torino F; Scerrati M; Navarra P; Graziani G
Glia; 2002 Oct; 40(1):44-54. PubMed ID: 12237842
[TBL] [Abstract][Full Text] [Related]
13. Delta MEKK3:ER* activation induces a p38 alpha/beta 2-dependent cell cycle arrest at the G2 checkpoint.
Garner AP; Weston CR; Todd DE; Balmanno K; Cook SJ
Oncogene; 2002 Nov; 21(53):8089-104. PubMed ID: 12444545
[TBL] [Abstract][Full Text] [Related]
14. Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
Pagani E; Falcinelli S; Pepponi R; Turriziani M; Caporaso P; Caporali S; Bonmassar E; D'Atri S
Int J Oncol; 2007 Feb; 30(2):443-51. PubMed ID: 17203227
[TBL] [Abstract][Full Text] [Related]
15. Early Chk1 phosphorylation is driven by temozolomide-induced, DNA double strand break- and mismatch repair-independent DNA damage.
Ito M; Ohba S; Gaensler K; Ronen SM; Mukherjee J; Pieper RO
PLoS One; 2013; 8(5):e62351. PubMed ID: 23667469
[TBL] [Abstract][Full Text] [Related]
16. Methylator-induced, mismatch repair-dependent G2 arrest is activated through Chk1 and Chk2.
Adamson AW; Beardsley DI; Kim WJ; Gao Y; Baskaran R; Brown KD
Mol Biol Cell; 2005 Mar; 16(3):1513-26. PubMed ID: 15647386
[TBL] [Abstract][Full Text] [Related]
17. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses.
Meyers M; Wagner MW; Hwang HS; Kinsella TJ; Boothman DA
Cancer Res; 2001 Jul; 61(13):5193-201. PubMed ID: 11431359
[TBL] [Abstract][Full Text] [Related]
18. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen.
Taverna P; Liu L; Hanson AJ; Monks A; Gerson SL
Cancer Chemother Pharmacol; 2000; 46(6):507-16. PubMed ID: 11138465
[TBL] [Abstract][Full Text] [Related]
19. p38 MAPK-dependent Nrf2 induction enhances the resistance of glioma cells against TMZ.
Ma L; Liu J; Zhang X; Qi J; Yu W; Gu Y
Med Oncol; 2015 Mar; 32(3):69. PubMed ID: 25691294
[TBL] [Abstract][Full Text] [Related]
20. Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin.
Moreland NJ; Illand M; Kim YT; Paul J; Brown R
Cancer Res; 1999 May; 59(9):2102-6. PubMed ID: 10232595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
